Dr Reddys Laboratories' Q3 FY 2025-26 Quarterly Results
- 1d ago
Result Summary
- Dr Reddys Laboratories Ltd reported a 1.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 5.8%.
- Its expenses for the quarter were up by 0.9% QoQ and 12.3% YoY.
- The net profit decreased 11.0% QoQ and decreased 15.3% YoY.
- The earnings per share (EPS) of Dr Reddys Laboratories Ltd stood at 14.52 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 9022.20 | 9152.20 | 8531.40 | -1.4% | 5.8% |
Total Expenses | 7481.30 | 7413.70 | 6661.30 | 0.9% | 12.3% |
Profit Before Tax | 1540.90 | 1738.50 | 1870.10 | -11.4% | -17.6% |
Tax | 353.60 | 408.00 | 470.10 | -13.3% | -24.8% |
Profit After Tax | 1189.60 | 1336.80 | 1404.20 | -11.0% | -15.3% |
Earnings Per Share | 14.52 | 16.17 | 16.94 | -10.2% | -14.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Dr Reddy's Laboratories Ltd is a prominent pharmaceutical company based in India. It is primarily engaged in the development, manufacture, and marketing of a wide range of pharmaceutical products. The company operates in various sectors, including generic medications, active pharmaceutical ingredients (APIs), and proprietary products. Dr Reddy's Laboratories serves a global market and is known for its focus on research and development to bring innovative healthcare solutions to patients worldwide. Recent developments in the company are not available, but it continues to be a significant player in the pharmaceutical industry.
Revenue
In the third quarter of fiscal year 2026 (Q3FY26), Dr Reddy's Laboratories reported a total income of ₹9022.20 crores. This represents a slight decline of 1.4% compared to the previous quarter (Q2FY26), where the total income was ₹9152.20 crores. However, when compared to the same quarter in the previous year (Q3FY25), which was ₹8531.40 crores, there is an increase of 5.8%. This indicates a year-over-year growth in total income, reflecting the company's ability to generate more revenue compared to the same period last year.
Profitability
The company's profitability in Q3FY26 shows a decrease in profit before tax, which amounted to ₹1540.90 crores. This marks an 11.4% reduction from the previous quarter's profit before tax of ₹1738.50 crores. Looking at the year-over-year performance, there is a 17.6% decrease from ₹1870.10 crores in Q3FY25. The tax expenses also decreased to ₹353.60 crores in Q3FY26, reflecting a 13.3% decline from Q2FY26 and a 24.8% reduction from Q3FY25. Consequently, the profit after tax for Q3FY26 was ₹1189.60 crores, representing an 11.0% decline quarter-over-quarter and a 15.3% drop year-over-year. Earnings per share stood at ₹14.52, down from ₹16.17 in Q2FY26 and ₹16.94 in Q3FY25, indicating a decrease of 10.2% and 14.3%, respectively.
Operating Metrics
The total expenses for Dr Reddy's Laboratories in Q3FY26 were reported at ₹7481.30 crores, which is a marginal increase of 0.9% from the previous quarter's expenses of ₹7413.70 crores. When compared year-over-year, total expenses have risen by 12.3% from ₹6661.30 crores in Q3FY25. This suggests a significant increase in operational costs over the past year. The financial data highlights a decline in profitability metrics such as profit before tax and profit after tax, while total income has shown year-over-year growth despite a slight quarterly decline. These figures provide insight into the company's financial health and its ability to manage expenses in relation to income generation.